Literature DB >> 23921607

Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease.

Silvia Ghezzi1, Laura Galli, Anna Kajaste-Rudnitski, Filippo Turrini, Sara Marelli, Daniela Toniolo, Claudio Casoli, Agostino Riva, Guido Poli, Antonella Castagna, Elisa Vicenzi.   

Abstract

OBJECTIVE(S): Tripartite motif-containing 22 (TRIM22) is an interferon-induced protein that inhibits HIV-1 transcription and replication in vitro. Two single nucleotide missense polymorphisms rs7935564A/G (SNP-1) and rs1063303C/G (SNP-2) characterize the coding sequence of human TRIM22 gene. We tested whether these variants affected the inhibitory effect of TRIM22 on HIV-1 replication and transcription and their potential association with HIV-1 disease.
DESIGN: The allelic discrimination was determined in 182 HIV-1-negative and among HIV-1-positive individuals with advanced disease progression (advanced progressors; n = 57), normal progressors (n = 76), and long-term nonprogressors (LTNPs; n = 95).
METHODS: Renilla luciferase activity was measured after infection of activated peripheral blood mononuclear cells (PBMCs) from an additional group of 61 blood donors with a recombinant HIV-1. HIV-1-long terminal repeat (LTR)-driven luciferase activity was tested in the presence of plasmid expressing TRIM22 variants in 293T cells. The SNP genotyping was determined by TaqMan assay.
RESULTS: HIV-1 replication was more efficient in PBMCs from donors with SNP-1G and SNP-2G than from those with SNP-1A and SNP-2C alleles. Consistently, TRIM22-GG enhanced, whereas TRIM22-AC restricted basal HIV-1 LTR-driven transcription. In vivo, SNP-1G homozygotes and A/G heterozygotes were more frequent in advanced progressors than in LTNPs [odds ratio (OR) = 2.072, P = 0.005] or in normal progressors (OR = 1.809, P = 0.022); in contrast, SNP-2 was not associated with any state of HIV-1 disease progression. Although SNP-2 distribution was similar among the groups, TRIM22-GG haplotype was found more frequently in advanced progressors than in LTNPs (P = 0.02).
CONCLUSION: TRIM22 genetic diversity affects HIV-1 replication in vitro and it is a potentially novel determinant of HIV-1 disease severity.
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921607     DOI: 10.1097/01.aids.0000432474.76873.5f

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy.

Authors:  Ronald Moura Rodrigues; Monserrat Plana; Felipe Garcia; Luisa Zupin; Louise Kuhn; Sergio Crovella
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

2.  Rapid development of broadly influenza neutralizing antibodies through redundant mutations.

Authors:  Leontios Pappas; Mathilde Foglierini; Luca Piccoli; Nicole L Kallewaard; Filippo Turrini; Chiara Silacci; Blanca Fernandez-Rodriguez; Gloria Agatic; Isabella Giacchetto-Sasselli; Gabriele Pellicciotta; Federica Sallusto; Qing Zhu; Elisa Vicenzi; Davide Corti; Antonio Lanzavecchia
Journal:  Nature       Date:  2014-10-05       Impact factor: 49.962

3.  Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.

Authors:  Luz M Medrano; Norma Rallón; Juan Berenguer; María A Jiménez-Sousa; Vicente Soriano; Teresa Aldámiz-Echevarria; Amanda Fernández-Rodríguez; Marcial García; Francisco Tejerina; Isidoro Martínez; José M Benito; Salvador Resino
Journal:  J Transl Med       Date:  2016-09-02       Impact factor: 5.531

4.  Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients.

Authors:  Eva Ramírez de Arellano; Francisco Díez-Fuertes; Francisco Aguilar; Humberto Erick de la Torre Tarazona; Susana Sánchez-Lara; Yolanda Lao; José Luis Vicario; Felipe García; Juan González-Garcia; Federico Pulido; Félix Gutierrez-Rodero; Santiago Moreno; Jose Antonio Iribarren; Pompeyo Viciana; Carlos Vilches; Manuel Ramos; Laura Capa; José Alcamí; Margarita Del Val
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

5.  Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes.

Authors:  Tejaswini S Reddi; Philipp E Merkl; So-Yon Lim; Norman L Letvin; David M Knipe
Journal:  PLoS Pathog       Date:  2021-02-01       Impact factor: 6.823

6.  On the relationship between tripartite motif-containing 22 single-nucleotide polymorphisms and COVID-19 infection severity.

Authors:  Nidhal Raheem Juhi Al-Kaabi; Sepideh Chodari Khameneh; Mohadeseh Montazeri; Mahsa Mardasi; Jalal Mosayebi Amroabadi; Fatemeh Sakhaee; Abolfazl Fateh
Journal:  Hum Genomics       Date:  2022-08-26       Impact factor: 6.481

7.  TRIM22 suppresses Zika virus replication by targeting NS1 and NS3 for proteasomal degradation.

Authors:  Shulong Zu; Chunfeng Li; Lili Li; Yong-Qiang Deng; Xiang Chen; Dan Luo; Qing Ye; Yi-Jiao Huang; Xiao-Feng Li; Rong-Rong Zhang; Nina Sun; Xianqi Zhang; Saba R Aliyari; Karin Nielsen-Saines; Jae U Jung; Heng Yang; Cheng-Feng Qin; Genhong Cheng
Journal:  Cell Biosci       Date:  2022-08-30       Impact factor: 9.584

8.  Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1 Polarization.

Authors:  Francesca Graziano; Giulia Aimola; Greta Forlani; Filippo Turrini; Roberto S Accolla; Elisa Vicenzi; Guido Poli
Journal:  Sci Rep       Date:  2018-09-24       Impact factor: 4.379

Review 9.  Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1.

Authors:  Greta Forlani; Mariam Shallak; Elise Ramia; Alessandra Tedeschi; Roberto S Accolla
Journal:  Retrovirology       Date:  2019-11-29       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.